Parkinson's Disease Research: Parkinson's disease is a chronic neurological disorder that affects body movement. Let us tell you about the latest discoveries in its treatment.

What is Parkinson's disease?

Japan Approves Stem Cell Therapy for Parkinson's: Japan has taken a major step forward in medical science by approving a new stem cell-based therapy. This therapy has been developed to treat Parkinson's disease and severe heart failure. According to media reports and the companies involved, with the approval of these treatments, it is expected that patients may begin to benefit within the coming months.

How will it work?

Pharmaceutical company Sumitomo Pharma announced that it has received approval to manufacture and sell its Parkinson's disease treatment, Amchepry. This treatment involves transplanting stem cells into a patient's brain, attempting to reactivate brain cells destroyed by the disease. Japan's Ministry of Health also approved another technology called ReHeart, developed by medical startup Cuorips, which involves creating specialized sheets of heart muscle. These sheets help the body form new blood vessels and can improve heart function.

When will it come to the market?

According to reports, these treatments could be available on the market by this summer. If this happens, it will be the world's first commercial medical product using iPS cells. Japanese scientist Shinya Yamanaka received the Nobel Prize in 2012 for his research on this technology. The unique feature of iPS cells is that they can be transformed into any type of cell in the body, increasing the possibilities for treating many diseases.

Relief for patients

Japan's Health Minister Kenichiro Ueno said he hoped this treatment would bring relief not only to patients in Japan but also around the world. He said the government would ensure that all necessary procedures are completed and that this treatment is made available to patients as soon as possible. According to Sumitomo Pharma, Amchepry has currently been granted conditional and time-limited approval. This means it will be considered a temporary license to allow new technology to reach patients quickly. This approval evaluated safety and effectiveness based on data from a limited number of patients, rather than large clinical trials like traditional medicines.

Is it safe?

A study conducted by researchers at Kyoto University found this therapy to be safe. Seven Parkinson's patients, aged 50 to 69, were included in the trial. Approximately 5 to 10 million stem cells were transplanted into the patients' brains. During two years of follow-up, no serious side effects were reported, and four patients experienced improvement in symptoms. Parkinson's disease is a chronic neurological disorder that affects body movement, often causing tremors and difficulty walking. Approximately 10 million people worldwide are affected by the disease.